All Sauce from Weekly Sauce:

Many Americans battling diabetes are turning to a new class of injected drugs that includes blockbusters like Ozempic (semaglutide) and Mounjaro (tirzepatide). But a new study finds half of patients who use these “second line” therapies — a class called GLP-1 RAs — quit them within a year. The main factor: Gastrointestinal issues like nausea, vomiting…  read on >  read on >

The diabetes and weight-loss drug Ozempic does not appear to harm a developing fetus when taken by pregnant women, a new study reports. Researchers found no elevated risk of birth defects among newborns of women who took medications to control their type 2 diabetes, compared with those who took insulin. During the decade-long study, researchers…  read on >  read on >

Saying “no” to a holiday invite might feel unforgivably rude, but people often overestimate the social consequences of turning down an invitation, psychologists report. More than three out of four people (77%) say they’ve accepted an invitation to an activity they didn’t want to attend because they were concerned about the consequences of declining. To…  read on >  read on >

Parents moaning over the noise from a new Christmas toy is a time-honored holiday tradition. But noisy playthings can do long-lasting damage to a child’s hearing, the American Academy of Audiology (AAA) is warning parents. Tiny ears are particularly susceptible to hearing damage, the AAA says. The inner ear contains delicate hair cells that don’t…  read on >  read on >

The holidays are all about parties, and parties are all about drinking wine. But if you’re a red wine lover, how do you avoid stained teeth? “When you drink red wine, you’re encountering a triple threat to your teeth’s whiteness: anthocyanins, which are the pigments in grapes that give red wine its rich color; tannins,…  read on >  read on >

Folks who take the blockbuster weight-loss med tirzepatide (Zepbound) may regain much of the weight they lost soon after discontinuing it, new research shows. A trial funded by Eli Lilly, the injected drug’s maker, found that “in patients with obesity or overweight, withdrawing tirzepatide led to substantial regain of weight.” On the other hand, continuing…  read on >  read on >